MannKind (MannKind) Long-Term Capital Lease Obligation : $3.9 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is MannKind Long-Term Capital Lease Obligation?

MannKind's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.9 Mil.

MannKind's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($4.6 Mil) to Sep. 2023 ($4.3 Mil) and declined from Sep. 2023 ($4.3 Mil) to Dec. 2023 ($3.9 Mil).

MannKind's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($1.0 Mil) to Dec. 2022 ($5.3 Mil) but then declined from Dec. 2022 ($5.3 Mil) to Dec. 2023 ($3.9 Mil).

MannKind Long-Term Capital Lease Obligation Historical Data

The historical data trend for MannKind's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Long-Term Capital Lease Obligation Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.51

1.20

1.04

5.34

3.93

MannKind Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.34	4.88	4.65	4.29	3.93

MannKind (NAS:MNKD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

MannKind Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of MannKind's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (MannKind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Executives

Michael Castagna	officer: Chief Commercial Officer	25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson	officer: VP & Assoc General Counsel	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder	officer: Chief Financial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank	officer: EVP Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: EVP Chief Operating Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh	officer: EVP Technical Operations	1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo	officer: Chief Commercial Officer	30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross	officer: Corp VP, Chief People Officer	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio	director	30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur	director
Sabrina Kay	director	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall	officer: Chief Medical Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley	officer: Chief Commercial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney	officer: Chief Compliance Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362